EUVIMEDEUVIMED entdecken
Crossref

Molecular Engineering of Quinolinium Cyanine Nanoagonist for Metastasis‐Suppressed NIR‐II Photothermal Immunotherapy

Yingzhe Wang, Anqi Shen, Mingwang Yang, Mengmeng Yuan, Zhonghua Liu, Danhong Zhou, Yongwei Huang, Xiaojing Li iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202504391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Yingzhe Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: Immunotherapy, Nanoparticles, Photothermal Therapy, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Henan, Key Scientific Research Projects of Colleges and Universities in Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the therapeutic promise of photothermal immunotherapy in triple‐negative breast cancer (TNBC), engineering second near‐infrared (NIR‐II) window‐responsive organic immunophotothermal agents persists as a critical hurdle. We address this gap by designing a molecularly tailored NIR‐II photothermal sensitizer (BOQCyCN), which concurrently enables tumor‐localized hyperthermia and systemic immunomodulation for combinatorial tumor clearance. Rational structure manipulation through benzyl donor‐cyano acceptor functionalization on a 4‐methylquinoline core induces a redshifted absorption maximum (λ max = 1022 nm), achieving deep‐tissue penetration within the NIR‐II biological therapeutic window. Co‐assembly with DSPE‐mPEG2000 generates stable BOQCyCN nanoparticles (NPs) exhibiting ultrahigh photothermal conversion (PCE, η = 62.9%) and irradiation resistance. At low irradiance (1064 nm, 0.6 W cm − 2 ), NPs initiate synergistic therapeutic cascades: (1) Primary tumor ablation (95% volume reduction) with amplified T‐cell infiltration (CD8 + : 5.5‐fold; CD4 + : 2.3‐fold); (2) Immunophenotype reprogramming via pro‐inflammatory M1 macrophage skewing (M1/M2: 2.55 vs. 0.33); (3) Metastatic suppression (96% reduced distal tumor burden). This thermo‐immunological nanoplatform establishes crosstalk between localized hyperthermia and antitumor immunity, advancing a translatable paradigm for TNBC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNanoparticlesPhotothermal TherapyTriple Negative Breast NeoplasmsCarbocyaninesQuinolinium CompoundsAnimalsFemaleCell Line, TumorHumansMiceInfrared RaysNeoplasm Metastasis

Stichwörter der Autor:innen

NIR‐II excitationimmune activationmolecular engineeringquinolinium cyanine

Substanzen

CarbocyaninesQuinolinium Compounds

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.

ORCID-Profile: Xiaojing Li

Förderung

  • Natural Science Foundation of Henan
  • Key Scientific Research Projects of Colleges and Universities in Henan Province

Zitieren

APA

Wang, Y., Shen, A., Yang, M., Yuan, M., Liu, Z., Zhou, D., Huang, Y., & Li, X. (2026). Molecular Engineering of Quinolinium Cyanine Nanoagonist for Metastasis‐Suppressed NIR‐II Photothermal Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202504391

Vancouver

Wang Y, Shen A, Yang M, Yuan M, Liu Z, Zhou D, et al. Molecular Engineering of Quinolinium Cyanine Nanoagonist for Metastasis‐Suppressed NIR‐II Photothermal Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202504391

BibTeX
@article{Wang2026,
  author = {Wang, Yingzhe and Shen, Anqi and Yang, Mingwang and Yuan, Mengmeng and Liu, Zhonghua and Zhou, Danhong and Huang, Yongwei and Li, Xiaojing},
  title = {Molecular Engineering of Quinolinium Cyanine Nanoagonist for Metastasis‐Suppressed NIR‐II Photothermal Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202504391}
}
Kostenlos starten →